Telavancin: Difference between revisions

Jump to navigation Jump to search
(#REDIRECT __NOTOC__)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Telavancin hydrochloride]]
{{Telavancin}}
{{CMG}}; {{AE}} {{chetan}}
 
==Overview==
'''Telavancin''' is a [[bactericidal]] [[lipoglycopeptide]] under trial for use in [[MRSA]] or other [[Gram-positive]] infections.
 
On October 19, 2007, the [[United States|US]] [[Food and Drug Administration]] issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. <ref>{{cite web |url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |format= |work= }}</ref>
 
==Category==
Glycopeptide
==US Brand Names==
VIBATIV<sup>®</sup>
==FDA Package Insert==
 
'''  [[Telavancin description|Description]]'''
'''| [[Telavancin clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Telavancin microbiology|Microbiology]]'''
'''| [[Telavancin indications and usage|Indications and Usage]]'''
'''| [[Telavancin contraindications|Contraindications]]'''
'''| [[Telavancin warnings and precautions|Warnings and Precautions]]'''
'''| [[Telavancin adverse reactions|Adverse Reactions]]'''
'''| [[Telavancin drug interactions|Drug Interactions]]'''
'''| [[Telavancin overdosage|Overdosage]]'''
'''| [[Telavancin clinical studies|Clinical Studies]]'''
'''| [[Telavancin dosage and administration|Dosage and Administration]]'''
'''| [[Telavancin how supplied|How Supplied]]'''
'''| [[Telavancin labels and packages|Labels and Packages]]'''
 
==Mechanism of action==
Like vancomycin, telavancin inhibits bacterial [[cell wall]] synthesis by binding to the <small>D</small>-[[Alanine|Ala]]-<small>D</small>-Ala terminus of the peptidoglycan in the growing cell wall (see [[Vancomycin#Pharmacology and chemistry|Pharmacology and chemistry of vancomycin]]). In addition, it disrupts bacterial [[Biological membrane|membranes]] by [[depolarization]].<ref name=HIG2005>{{Cite journal| url=http://aac.asm.org/cgi/content/full/49/3/1127| title=Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus| journal=Antimicrobial Agents and Chemotherapy| pages=1127–1134| volume=49| issue=3| year=2005| doi=10.1128/AAC.49.3.1127-1134.2005| pmid=15728913| last1=Higgins| first1=DL| last2=Chang| first2=R| last3=Debabov| first3=DV| last4=Leung| first4=J| last5=Wu| first5=T| last6=Krause| first6=KM| last7=Sandvik| first7=E| last8=Hubbard| first8=JM| last9=Kaniga| first9=K| pmc=549257}}</ref><ref>{{Cite journal
| author = H. Spreitzer
| date = 2 February 2009
| title = Neue Wirkstoffe - Telavancin
| journal = Österreichische Apothekerzeitung
| issue = 3/2009
| language = German
}}</ref>
 
{{Reflist|2}}
 
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Latest revision as of 18:56, 9 February 2015